These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 28576628)
1. Incidence of Torsade de Pointes in a tertiary hospital population. Vandael E; Vandenberk B; Vandenberghe J; Pincé H; Willems R; Foulon V Int J Cardiol; 2017 Sep; 243():511-515. PubMed ID: 28576628 [TBL] [Abstract][Full Text] [Related]
2. Cases of drug-induced Torsade de Pointes: a review of Belgian cases in the EudraVigilance database. Vandael E; Vandenberk B; Vandenberghe J; Willems R; Foulon V Acta Clin Belg; 2017 Dec; 72(6):385-390. PubMed ID: 28335691 [TBL] [Abstract][Full Text] [Related]
3. Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium. Vandael E; Vandenberk B; Vandenberghe J; Spriet I; Willems R; Foulon V Int J Clin Pharm; 2016 Apr; 38(2):310-20. PubMed ID: 26749342 [TBL] [Abstract][Full Text] [Related]
4. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany. Sarganas G; Garbe E; Klimpel A; Hering RC; Bronder E; Haverkamp W Europace; 2014 Jan; 16(1):101-8. PubMed ID: 23833046 [TBL] [Abstract][Full Text] [Related]
5. Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise? Romero J; Baldinger SH; Goodman-Meza D; Engstrom K; Valencia CR; Golive A; Medrano F; Rangasamy S; Makkiya M; Fisher JD; Gross J; Krumerman A; Kim S; Garcia MJ; Di Biase L; Ferrick KJ J Interv Card Electrophysiol; 2016 Jan; 45(1):37-45. PubMed ID: 26589717 [TBL] [Abstract][Full Text] [Related]
6. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias. Topilski I; Rogowski O; Rosso R; Justo D; Copperman Y; Glikson M; Belhassen B; Hochenberg M; Viskin S J Am Coll Cardiol; 2007 Jan; 49(3):320-8. PubMed ID: 17239713 [TBL] [Abstract][Full Text] [Related]
7. Prevalence of Medication Associated with QTc Prolongation Used Among Critically Ill Patients. Al-Azayzih A; Al-Qerem W; Al-Azzam S; Muflih S; Al-Husein BA; Kharaba Z; Kanaan RJ; Rahhal D Vasc Health Risk Manag; 2024; 20():27-37. PubMed ID: 38318252 [TBL] [Abstract][Full Text] [Related]
8. Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: A review and pharmacovigilance study. Salem JE; Bretagne M; Lebrun-Vignes B; Waintraub X; Gandjbakhch E; Hidden-Lucet F; Gougis P; Bachelot A; Funck-Brentano C; Arch Cardiovasc Dis; 2019 Nov; 112(11):699-712. PubMed ID: 31477476 [TBL] [Abstract][Full Text] [Related]
9. Assessment of drug-induced torsade de pointes risk for hospitalized high-risk patients receiving QT-prolonging agents. Jardin CG; Putney D; Michaud S Ann Pharmacother; 2014 Feb; 48(2):196-202. PubMed ID: 24301687 [TBL] [Abstract][Full Text] [Related]
10. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Vandael E; Vandenberk B; Vandenberghe J; Spriet I; Willems R; Foulon V Int J Clin Pharm; 2017 Apr; 39(2):424-432. PubMed ID: 28281228 [TBL] [Abstract][Full Text] [Related]
11. Systemic inflammation as a novel QT-prolonging risk factor in patients with torsades de pointes. Lazzerini PE; Laghi-Pasini F; Bertolozzi I; Morozzi G; Lorenzini S; Simpatico A; Selvi E; Bacarelli MR; Finizola F; Vanni F; Lazaro D; Aromolaran A; El Sherif N; Boutjdir M; Capecchi PL Heart; 2017 Nov; 103(22):1821-1829. PubMed ID: 28490617 [TBL] [Abstract][Full Text] [Related]
12. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation? Mayet S; Gossop M; Lintzeris N; Markides V; Strang J Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918 [TBL] [Abstract][Full Text] [Related]
13. QTc Prolongation in Poison Center Exposures to CredibleMeds List of Substances with "Known Risk of Torsades de Pointes". Ryan K; Benz P; Zosel A; Farkas A; Theobald J Cardiovasc Toxicol; 2022 Sep; 22(9):866-877. PubMed ID: 35930218 [TBL] [Abstract][Full Text] [Related]
15. Acquired long QT syndrome from stress cardiomyopathy is associated with ventricular arrhythmias and torsades de pointes. Madias C; Fitzgibbons TP; Alsheikh-Ali AA; Bouchard JL; Kalsmith B; Garlitski AC; Tighe DA; Estes NA; Aurigemma GP; Link MS Heart Rhythm; 2011 Apr; 8(4):555-61. PubMed ID: 21146632 [TBL] [Abstract][Full Text] [Related]
16. Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports. Vieweg WV; Hasnain M; Hancox JC; Baranchuk A; Digby GC; Kogut C; Crouse EL; Koneru JN; Deshmukh A; Pandurangi AK Psychopharmacology (Berl); 2013 Aug; 228(4):515-24. PubMed ID: 23812796 [TBL] [Abstract][Full Text] [Related]
17. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938 [TBL] [Abstract][Full Text] [Related]
18. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes? Samuelov-Kinori L; Kinori M; Kogan Y; Swartzon M; Shalev H; Guy D; Ferenidou F; Mashav N; Sadeh B; Atzmony L; Kliuk-Ben-Basat O; Steinvil A; Justo D J Electrocardiol; 2009; 42(4):353-357.e1. PubMed ID: 19261294 [TBL] [Abstract][Full Text] [Related]
19. A case series of drug-induced long QT syndrome and Torsade de Pointes. Tong KL; Lau YS; Teo WS Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578 [TBL] [Abstract][Full Text] [Related]
20. Prevalence and determinants of QT interval prolongation in medical inpatients. Pasquier M; Pantet O; Hugli O; Pruvot E; Buclin T; Waeber G; Aujesky D Intern Med J; 2012 Aug; 42(8):933-40. PubMed ID: 21299787 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]